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Doxorubicin (DOX) is an effective chemotherapeutic drug for many types of 
cancer. However, the deleterious effect of DOX is also observed in heart and skeletal 
muscles. Doxorubicin-induced reactive oxygen species (ROS) in mitochondria causes 
muscle dysfunction and atrophy leading to the release of cytochrome c (cyt c) and 
activation of caspase-9 (casp-9) which cause apoptosis, a programmed cell death in 
skeletal muscles. Previous studies have proposed that creatine (Cr) possesses antioxidant 
capacity by reducing ROS in oxidative environment. Creatine supplements have shown to 
reduce mitochondrial ROS production and decrease apoptotic enzyme activities in 
oxidative skeletal muscles; however, Cr’s effects on DOX-induced apoptosis are not yet 
fully understood. PURPOSE: To investigate the effects of two different Cr 
supplementation protocols on cyt c and casp-9 expression in skeletal muscles from rats 
treated with DOX at two different time points. METHODS: Male Sprague Dawley rats 
(n=120) were randomly assigned to one of the three different diet treatments: control 
(CON, n=40), 2% Cr for four-week (2% Cr, n=40), and the Cr loading consisting of 4% 
Cr for one-week followed by three-week of 2% Cr (4% Cr, n=40). Then, each group was 
randomly assigned to two different time points for the drug administration: one-day prior 
to the sacrifice (1, n=20) and three-day prior to the sacrifice (3, n=20). Lastly, each group 
 iv 
was randomly assigned to two different drug treatments: 3 mL of saline (SAL, n=10) and 
15 mg/kg of DOX (DOX, n=10). The left soleus (SOL) and left extensor digitorum 
longus (EDL) were collected after anesthesia and homogenized. A western blot assay was 
used to determine protein expression of cyt c and casp-9. RESULTS: No significant 
effects of Cr supplementation and DOX administration on cyt c and casp-9 expressions 
were observed in both the SOL and EDL (p>0.05). The interaction between the Cr 
supplementation and the DOX injection was also not significant (p>0.05).  A trend 
toward a decrease in cyt c and casp-9 expression was observed in the 4% Cr group of 3-
SOL and 1-EDL with the DOX injection, but there were no significant differences 
(p>0.05). CONCLUSIONS: Even though there were no significant main effects of Cr 
diet treatment, DOX administration and no interactions, a potential trend indicated that 
the Cr loading protocol may prevent apoptosis by attenuating the expressions of cyt c and 
casp-9 in skeletal muscles. Further research with measuring oxidative stress level, protein 
synthesis and degradation, and amount of Cr supplementation consumed needs to be 
conducted in order to fully understand the mechanism of the Cr supplement and the DOX 
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Chemotherapy is one of the major cancer treatments, along with surgery, radiation 
therapy, and immunotherapy. The effect of chemotherapy was originated from World 
War I when mustard gas was used and found to possess the “anti-carcinogenic” effect. 
(Berenblum, 1929). Since then, scientists investigated the effect of chemotherapy for 
cancer treatment, and it was introduced to clinics in the early 20th century (Papac, 2001). 
Chemotherapy utilizes one or more chemotherapeutic agents to prolong life, reduce 
symptoms of cancer, and potentially cure certain types of cancer. Ideally, 
chemotherapeutic agents should specifically target neoplastic cells, also called tumors, 
and decrease the size of tumors by poisoning the inside of the cell, leading to an 
inhibition of mitosis, or cell division. Anti-cancer drug-induced cytotoxicity also has 
been observed in normal cells due to a lack of specificity and increased the side effects of 
chemotherapeutic drugs including hair loss, anemia, fatigue, and weight loss (Johnstone, 
Ruefli, & Lowe, 2002; Coates et al., 1983).  
 Doxorubicin (DOX) is one of many chemotherapeutic drugs and frequently used 
to treat many types of cancers, including leukemia, lymphomas, solid tumors, and 
sarcomas (Lipshult et al., 1991). The mechanism of DOX is that the production of 
reactive oxygen species (ROS) through its metabolism damages cell membranes, 
proteins, and deoxyribonucleic acid (DNA) resulting in cell death (Minotti, Menna, 




effective; however, DOX-induced toxicity also has been observed to cause critical 
damage in normal tissues including heart and skeletal muscles (Hydock, Lien, Jensen, 
Schneider, & Hayward, 2011). In skeletal muscle, DOX treatment decreased force 
production and the level of contractile proteins and initiated cell death because of DOX-
induced ROS production (Min et al., 2015). Therefore, the usage of DOX treatment has 
been limited in the clinics due to its toxicity in healthy tissues. 
 Reactive oxygen species (ROS) are molecules that contain oxygen and are 
produced by the metabolism of oxygen (Devasagayam et al., 2004). Reactive oxygen 
species are often taken up by the antioxidant defense enzyme such as superoxide 
dismutase (SOD) to prevent ROS from reacting with other molecules. (Valko et al., 
2007). The accumulation of ROS, known as oxidative stress, damages macromolecules 
such as carbohydrates, lipids, protein, and DNA and may initiate apoptosis (Birben, 
Sahiner, Sackesen, Erzurum, & Kalayci, 2012). It is essential to tightly regulate oxidative 
stress because it can cause many pathological conditions including neurodegenerative 
disease, gene mutations, inflammatory disease, chronic fatigue syndrome, and cancer 
(Sies, Stahl, & Sundquist, 1992). 
 Apoptosis is a tightly regulated programmed cell death, and it is a normal event as 
a homeostatic mechanism in tissues (Alberts et al., 2008). Apoptosis is often triggered by 
physical or pathological conditions such as DNA damage and the overproduction of ROS 
(Norbury, & Hickson, 2001; Yuan, Murrell, Trickett, & Wang, 2003). This programmed 
cell death is often initiated by the release of apoptosis-inducing factors (AIF) such as 
cytochrome c and the activation of proapoptotic proteins including caspase-9 and 




much apoptosis because it can cause neurodegenerative diseases, ischemic damage, and 
atrophy in tissues (Elmore, 2007). 
 Creatine (Cr) is an organic compound that is produced primarily in the liver and 
consumed through a regular diet (Walker, 1979). The ergogenic effect of Cr as a 
supplement is well known to enhance exercise performance such as power, strength, and 
speed with exercise training (M. Bemben, D. Bemben, Loftiss, & Knehans, 2001; Skare, 
Skadberg, & Wisnes, 2001). Recently, researchers have proposed a direct antioxidant 
capacity of Cr. Creatine as a supplement has shown to scavenge free radicals, specifically 
superoxide anion (•O−2) and peroxynitrite (OONO
−) and reduce the level of free radicals 
induced by exercise in skeletal muscle (Deminice & Jordao, 2012; Guimarães-Ferreira et 
al., 2012; Lawler, Barnes, Wu, Song, & Demaree, 2002). This direct antioxidant capacity 
of Cr has been debatable due to unclear exact mechanisms; however, the creatine 
supplement seemed to activate an intracellular signaling pathway that regulates 
mitochondrial function in oxidative skeletal muscle and reduce apoptotic enzyme 
activities by activating the anti-apoptotic pathway in ischemic heart tissue (Ceddia & 
Sweeney, 2004; Caretti et al., 2010). 
 Therefore, doxorubicin treatment is well-known to be effective in many types of 
cancers; however, the mechanism of DOX induces toxicity in heart and skeletal muscles 
by producing an excessive amount of ROS. Doxorubicin-induced damage in skeletal 
muscles can lead to decrease force production and contractile proteins, causing apoptosis. 
The direct antioxidant effect of Cr supplement can be potentially one of preventive 





Statement of Purpose 
 
 The main purpose of this study was to investigate the effects of in vivo DOX 
administration at two different time points prior to rat sacrifice (one- and three-day) on 
the expressions of the apoptotic initiator proteins cytochrome c and caspase-9 in type I 
and type II skeletal muscle fibers. The second purpose of this study was to explore the 
effects of two different Cr supplementations, 2% Cr supplementation for four-week and 
Cr loading treatment consisting of 4% Cr supplementation for one-week then followed by 
2% Cr supplementation for three-week, on cytochrome c and caspase-9 expressions in 
type I and type II skeletal muscle fibers. The third purpose of this study was to examine 
the interaction between the Cr supplementation and the DOX administration in type I and 
type II skeletal muscle fibers.  
Research Hypotheses 
 
H1 DOX administration at 1-day and 3-day prior to rat sacrifice will increase 
cytochrome c and caspase-9 expressions in both the soleus (SOL) and 
extensor digitorum longus (EDL). 
 
H2 Both Cr supplementation treatments, 2% Cr and 4% Cr, will attenuate the 
increased cytochrome c and caspase-9 protein expressions in both the SOL 
and EDL. 
 
H3 Both Cr supplementations treatment, 2% Cr and 4% Cr, will attenuate the 
effects of DOX on cytochrome c and caspase-9 expressions in both the 
SOL and EDL. 
 
H4 The Cr loading treatment, one week of 4% Cr supplementation followed 
by three weeks of 2% Cr supplementation, will provide the greatest degree 
of protection against the effects of DOX on cytochrome c and caspase-9 










REVIEW OF LITERATURE 
Doxorubicin (DOX) 
 
Doxorubicin (DOX) is an anthracycline chemotherapeutic agent used to treat 
leukemia, lymphomas, and solid tumors such as breast, lung, gastric, and soft tissue 
sarcomas (Lipshult et al., 1991). Doxorubicin is composed of daunosamine and an 
addition of hydroxyl group at carbon 14 position (Takemura & Fujiwara, 2007). The 
main metabolic pathway for DOX is going under redox cycling where the reduction of 
two electrons yields doxorubicinol, a secondary alcohol, or one electron reduction with 
oxidoreductases including cytosolic nicotinamide adenine dinucleotide phosphate 
hydrogen, (NAD(P)H), xanthine oxidase, and synthases lead to form a doxorubicin-
semiquinone radical. Due to its structure, the doxorubicin-semiquinone is an unstable 
metabolite so that it converts back to doxorubicin immediately. During this process, it 
releases reactive oxygen species (ROS), which can lead to lipid peroxidation, the 
oxidative degradation of fatty acids. Reactive oxygen species-induced lipid peroxidation 
can lead to membrane damage, DNA damage, oxidative stress, and eventually, it can 
continue to apoptotic pathways of cell death (Doroshow, 1986). The DOX chemotherapy 
has been effective in fighting against cancer by inducing DNA damage with the 
inhibition of topoisomerase II, an enzyme which manages DNA tangles and supercoils 
and by increasing oxidative stress which will lead to ROS-induced apoptosis (Gewirtz, 




While the DOX chemotherapy is highly effective in DNA damaging for cancer cells, it 
also can damage healthy cells, especially in heart tissue with an increase in DOX-induced 
ROS causing cardiotoxicity (L'Ecuyer et al., 2006; Yoshida, Shiojima, Ikeda, & Komuro, 
2009). Therefore, DOX treatment has been limited to decrease the damage in normal 
healthy tissues. 
Reactive Oxygen Species (ROS) 
 
Reactive oxygen species are atoms or a group of atoms that have one or more 
unpaired electrons such as superoxide (•O−2), hydrogen peroxide (H2O2), hydroxyl radical 
(·OH), and hydroperoxyl (HO2). They are endogenously generated in the process of 
mitochondrial oxidative phosphorylation, or the interaction of exogenous factors can lead 
to the accumulation of ROS. When there is an imbalance between the production of ROS 
and the cellular antioxidant defenses, oxidative stress occurs and causes ROS-mediated 
damage in nucleic acids, proteins, and lipids which can directly or indirectly result in 
cancer, diabetes, neurodegeneration, and atherosclerosis (Ray, Huang, & Tsuji, 2012). 
Reactive oxygen species are often produced by oxidoreductases such as 
NAD(P)H, and xanthine oxidase in cell membranes, mitochondria, and endoplasmic 
reticulum. Mitochondrial ROS are generated in the process of oxidative phosphorylation 
where mitochondria convert energy into a form of adenosine triphosphate (ATP) as a 
product of citric acid cycle, fatty acid oxidation, and amino acid oxidation (Muller, 
2000). The process of ATP synthesis in mitochondria involves the transport of hydrogen 
ions (H+) across the inner mitochondrial membrane utilizing an enzymatic series of 
electron donors and acceptors, called the electron transport chain (ETC). The first 




carrier from the citric acid cycle. The electrons get passed down to coenzyme Q, which 
also accepts electrons from complex II. Coenzyme Q continues to pass down electrons to 
complex III, then to cytochrome c. The final complex is complex IV, where oxygen is 
reduced to water (H2O) (Han, Williams, & Cadenas, 200; Muller, 2000). In the process of 
passing electrons to oxygen, a small number of electrons do not complete the whole 
series which results in converting oxygen into the free radical, superoxide (•O−2) by 
NADPH and xanthine oxidase (Muller, Lustgarten, Jang, Richardson, & Van Remmen, 
2007). Superoxide is mostly generated during complex I and III and initiates lipid 
peroxidation when it converts to hydrogen peroxide (H2O2) (Li et al., 2013). Due to the 
toxicity of •O−2 at high concentration, the antioxidant defense enzyme, superoxide 
dismutase (SOD), efficiently catalyzes superoxide into H2O2 (Valko et al., 2007). H2O2 
can be converted to hydroperoxyl (·OH) which is highly reactive and can lead to damage 
of macromolecules, including nucleic acids, carbohydrate, lipids, and amino acids. To 
prevent the accumulation of ·OH, H2O2 can also be quickly decomposed by the 




Apoptosis is defined as a form of programmed cell death which is a highly 
regulated and controlled process in multicellular organisms unlike necrosis, a form of 
traumatic cell death from acute cell injuries (Alberts et al., 2008). Apoptosis is a normal 
event during development and aging as a homeostatic mechanism in tissues. This 
programmed cell death can act as an immunity defense system when cells are damaged 




Apoptosis can be induced by direct exposure of cells to ROS, including H2O2 and ·OH 
(Buttke & Sandstrom, 1994; Norbury & Hickson, 2001). Also, chemotherapeutic drugs 
result in DNA damage and can lead to a p53-dependent apoptotic pathway in cancer 
cells. Either too little or too much of apoptosis is critical in many human conditions, 
including neurodegenerative diseases, ischemic damage, autoimmune disorders, atrophy, 
and many types of cancers (Elmore, 2007).  
 Apoptosis can be activated by one of two main apoptotic pathways: the 
extrinsic/death receptor pathway and the intrinsic/mitochondrial pathway. The extrinsic 
pathway involves death receptors that are members of the tumor necrosis factor (TNF) 
receptor gene superfamily (Locksley, Killeen, & Lenardo, 2001). The TNF receptor 
family contains a cytoplasmic “death domain” that transmits the death signal to the 
intracellular signaling pathways from the cell surface. Once extracellular ligands 
including FasL and TNF-α bind to the TNF receptors with the death domain, a death-
inducing signaling complex (DISC) is formed, leading to the activation of caspases, 
essential protease enzymes in apoptosis. The cleaved caspases (activation form of 
caspase) can activate other procaspases (an inactivated form of caspase) and allow to 
initiate the caspase cascade leading to apoptosis (Elmore, 2007; Peter & Krammer, 1998).  
The intrinsic apoptosis pathway is initiated in response to non-receptor-mediated 
stimuli including radiation, hypoxia, increased intracellular concentration of free fatty 
acids, and ROS (Cotran & Kumar, 1998; Hardy et al., 2003; Mattson & Chan, 2003). 
These stimuli that initiate the intrinsic pathway produce intracellular signals which can 
act directly on targets of a cell and are the events initiated by mitochondria. p53-mediated 




suppressor gene p53 is a transcription factor that regulates the cell cycle. The apoptotic 
stimuli such as DNA damage at the G1/S phase of the cell cycle activate p53 and initiate 
the apoptosis. The activation of p53 regulates Bcl-2 family of the proteins which play a 
role in mitochondrial membrane permeability. The proteins of the Bcl-2 family can be 
either pro-apoptotic or anti-apoptotic. For example, Bax and Bak are the pro-apoptotic 
proteins of the Bcl-2 family and formed an oligomeric pore in the outer mitochondrial 
membrane.  
The anti-apoptotic proteins Bcl-2 and Bcl-x physically block the oligomeric pore 
of Bax and Bak and prevents the release of cyt c from mitochondria to the cytoplasm. 
The activation of p53 by DNA damage recognition leads to a conformational change in 
Bax/Bak and Bcl-2/Bcl-x resulting in the release of cytochrome c (cyt c) from inner 
mitochondria to the cytoplasm (Cory & Adams, 2002; Elmore, 2007; Schuler & Green, 
2001). Then, the mitochondria-mediated apoptosis occurs when the release of cyt c 
activates apoptotic protease activating factor-1 (Apaf-1) as well as procaspase-9 (Saelens 
et al., 2004). Cleaved caspase-9 is an initiator caspase of caspase cascade and leads to 
activating the effector caspases such as caspase-3, -6, and -7 resulting in apoptosis (Rai, 
Tripathi, Sharma, & Shukla, 2005). Additionally, Smac/Diablo, the secondary 
mitochondria-derived activator of caspases, binds to inhibitor of apoptosis proteins and 
enhances caspases activation (Susin et al., 1999).  
In addition, calcium (Ca2+) plays an essential role in the initiation of the intrinsic 
apoptotic pathway. The homeostasis of Ca2+ is tightly regulated in mitochondria. The 
concentration of Ca2+ in mitochondria can be increased by a Ca2+ uniporter, transporting 




initiation of apoptosis is associated with an opening of mitochondrial permeability 
transition (MPT) pore. The large accumulation of Ca2+ in mitochondria can lead to 
osmotic swelling, and then it ends up with bursting the mitochondrial membrane. The 
rupture of the membrane can release cyt c into the cytosol through the opening of MPT 
(Orrenius, Gogvadze, & Zhivotovsky, 2015). 
Additionally, Ca2+ can dephosphorylate the Bcl-2 family, including Bax and Bak 
by the protein phosphate calcineurin which is often activated by Ca2+. This 
dephosphorylation of Bax and Bak triggers the unblock of Bcl-2 and Bcl-x on Bax/Bak 
on the outer mitochondrial membrane and leads to the release of cyt c to the cytoplasm 
(Wang, Lin-Shiau, & Lin, 1999). The Ca2+-mediated activation of calpain in the 
mitochondria can initiate apoptosis in the cell as well. The entry of Ca2+ into the inner 
mitochondria can directly activate mitochondrial calpain. Then calpain promotes the 
cleavage of cardiolipin, which anchors apoptosis-inducing factors (AIF) including cyt c 
in the inner mitochondrial membrane. The release of AIF via cleavage of cardiolipin into 
the cytosol can cause DNA fragmentation and initiate cell death (Orrenius et al., 2015). 
Cytochrome c (Cyt c) 
Cytochrome c (cyt c) is a highly water-soluble hemeprotein involved in the ETC 
in the mitochondria. The heme group of cyt c accepts and transfers electrons to the 
complex IV, the final complex of ETC (Han, Williams, & Cadenas, 2001; Muller, 2000). 
Cyt c is also involved in the initiation of apoptosis. It binds to cardiolipin in the inner 
mitochondrial membrane, which prevents it from releasing cyt c out of mitochondria and 
initiating apoptosis when there is no intracellular apoptotic signal. Without apoptotic 




apoptotic pathway. When an apoptotic stimulus is present such as ROS produced by 
mitochondria, cyt c becomes oxidized by NAD(P)H and causes an opening of the MPT 
pore. Then the oxidized cyt c is detached from cardiolipin and released through the MPT 
pore into the cytoplasm (Matsuura, Canfield, Feng, & Kurokawa, 2016). Also, the release 
of cyt c is highly regulated by the Bcl-2 family via p53 mediated apoptotic pathway. The 
p53-mediated conformational change of Bax/Bak makes an opening on mitochondrial 
membrane and allow cyt c to pass through the oligomeric pore of Bax/Bak from 
mitochondria to the cytoplasm (Meyer, Kim, & Penn, 2006). The release of cyt c triggers 
the formation of the apoptosome, which is assembled with a one-to-one ratio of cyt c and 
Apaf-1. The sevenfold symmetric structure of apoptosomes leads to an activation of 
procaspase-9, an initiator caspase of caspase cascade resulting in apoptosis (Ferraro, 
Fuoco, Strappazzon, & Cecconi, (2010). 
 Karpinich, Tafani, Rothman, Russo, and Farber (2002) showed the importance 
of cyt c in maintaining healthy cells has been shown in their study. The L929 mouse 
fibroblasts were treated with ten µM of etoposide, which is a topoisomerase II inhibitor 
and induces DNA damage. The etoposide-treated fibroblasts showed expression of cyt c 
in the cytoplasm by western blot assay after 24 hours. Also, the percentage of dead cells 
increased by 48.1 ± 2.4 % after 72 hours of etoposide treatment. This data suggests that 
the release of cyt c induced cell death to regulate fibroblasts with DNA damage induced 
by etoposide. In addition, oxidative stress by ROS can induce the cyt c release in the 
cytoplasm. Human tendon was treated with high concentration (50 µM) of H2O2 for 12 
hours, and a significant increase of apoptotic cells (8%) was detected compared to the 




the release of cyt c was expressed by western blot assay while there was no detectable cyt 
c expression in control cultured human tendon cells. The oxidative stress-induced cyt c 
release resulted in a threefold increase in caspase-3 activity (Yuan et al., 2003).  
Another study suggested that lipid peroxidation induces cyt c release from 
mitochondria by breaking the bond of cyt c and cardiolipin. The bovine heart was treated 
with oxygen gas overnight leading to an increase in the formation of a conjugated diene, 
the marker for lipid peroxidation. The lipid peroxidation led to a less effective activity 
between cardiolipin and cyt c resulting in release of cyt c to the cytoplasm from 
mitochondria (Shidoji, Hayashi, Komura, Ohishi, & Yagi, 1999). Additionally, it has 
been shown that the increase in the release of cyt c from mitochondria was induced by 
Ca2+-mediated mitochondrial swelling in the brain and liver tissue of rats. The induction 
of MPT was observed using a spectrophotometer, and the rapid reduction of light 
absorbance indicated a rise in mitochondrial swelling. The mitochondria from both brain 
and liver tissues, treated with 100 µM Ca2+, caused a large decrease in light absorbance. 
This Ca2+-induced mitochondrial swelling led to an increase in the release of cyt c from 
mitochondria, detected by western blot assay (Kobayashi et al., 2003). These studies 
suggested that the release of cyt c can be caused by DNA damage, ROS-induced 
oxidative stress, lipid peroxidation, or Ca2+-induced mitochondrial swelling leading to 
cell death.  
Caspase-9 (Casp-9) 
 
Caspase-9 (casp-9) is a family of cysteine-aspartic protease (caspase) involved in 
apoptosis and found in the mitochondria, cytosol, and nucleus. Casp-9 is an initiator 




tissues. Procaspase-9 is the form expressed in an inactive proenzyme, and cleaved 
caspase-9 is the active form of proenzyme caused by apoptotic signals (Kuida, 2000). 
Caspase-9 has three domains: N-terminal pro-domain, large subunit, and a small subunit. 
The N-terminal pro-domain contains the caspase activation domain (CARD) where it 
binds to CARD of Apaf-1 (Li et al., 2017). The release of cyt c and activated Apaf-1 by 
apoptotic signals cause dimerization of procaspase-9 resulting in formation of cleaved 
casp-9. Once it is activated, the caspase cascade initiates with cleaved casp-9 cleaving 
another procaspase-9 for its dimerization or activating the executioner caspases including 
caspase-3, -6, and -7, leading to apoptosis (Druskovic, Suput, & Milisav, 2006; 
Zhivotovsky, Samali, Gahm, & Orrenius, 1999). 
Cleaved casp-9 is an essential enzyme to initiate apoptosis via caspase cascade in 
mitochondria. In the HeLa cell with immunodepletion of casp-9, it failed to activate the 
executioner caspase, caspase-3. According to Li et al., (1997), the protease cascade 
leading to apoptosis was initiated as soon as cleaved casp-9 rapidly activated caspase-3 in 
normal healthy HeLa cell. In another experiment, ROS such as H2O2 induced p53-
dependent apoptosis. The loss of mitochondrial membrane permeability due to an 
injection of H2O2 (25 and 50 µM) in HeLa cells resulted in the release of cytochrome c 
leading to a significant increase in the cleavage of procaspase-9 compared to the control 
without the H2O2 treatment (p<0.01). The 25 µM H2O2-induced activation of procasp-9 
significantly increased the activation of the caspase-3-mediated apoptosis (p<0.001) 
(Pallepati & Averill-Bates, 2011). In Wang et al. study (1999), flavonoid-induced ROS 
activated the procaspase-9 in human promyelocytic leukemia HL-60 cells treated with 60 




procaspase-9 was increased after 12 hours of flavonoid treatment by western blot assay, 
and it was consistent with DNA fragmentation and the activity of caspase-3. The study 
suggested that flavonoid metabolic process induced the ROS production due to its 
structure which led to mitochondrial dysfunction, and resulted in the activation of casp-9 
and caspase-3, leading to apoptosis. In a cancer cachexia mouse model, increased 
caspase-dependent proteolytic activity was observed due to weight loss with the depletion 
of skeletal muscle and adipose tissue. Among mice with weight loss (from 2% to 25%) 
after MAC 16 or MAC 13 tumor implantation, the activity of caspase-9 and caspase-3 
increased by 177% and 98%, respectively, in gastrocnemius muscles (Belizário, Lorite, & 
Tisdale, 2001). This suggested that the weight loss was caused by caspase-dependent 
apoptosis in skeletal muscle cells. From these previous studies, cleaved caspase-9 plays a 
critical apoptotic initiator enzyme which induces the activation of caspase-3, leading to 





Lipid peroxidation is the oxidative degradation of fatty acids, especially 
polyunsaturated fatty acids due to their multiple double bonds in between methylene 
bridges that possess primarily reactive hydrogen atoms. The lipid peroxidation is initiated 
by ROS such as ·OH and H2O2 taking electrons from lipids in the cell membrane 
producing the fatty acid radicals. The fatty acid radical is not a stable molecule by losing 
an electron, which leads to reacting with oxygen, forming peroxyl-fatty acids. The final 
products of lipid oxidation are malondialdehyde (MDA) and 4-hydroxynonenal (HNE), 




and HNE are considered to be mutagenic and causal agents for many diseases such as 
diabetes, chronic inflammation, neurodegenerative disease, osteoarthritis, and different 
types of cancer (Tiku, Narla, Jain, & Yalamanchili, 2007; Zarkovic, 2003).  
 According to Myers et al. (1977), DOX-induced lipid peroxidation results from 
increased ROS production by DOX metabolism with NAD(P)H and xanthine oxidase. 
Their study showed that MDA was detected in normal mouse cardiac tissues two days 
after the injection of DOX (15 mg/kg) in the peritoneum while the control cardiac tissues 
without the DOX injection had no MDA detected. After four days of the injection, MDA 
reached a peak concentration of 53 ± 10 μM.  (Myers et al., 1977). Another study found 
that the formation of conjugate diene-containing lipids, resulted from peroxidation of 
unsaturated lipids, increased in cultured cardiomyocytes of Wistar rats exposed to 1 μM 
DOX. The DOX-treated cardiomyocyte had a significant increase of 1.6 fold in 
comparison to the cells not exposed to DOX in the first three hours after drug exposure 
(p<0.01). Also, there was a linear correlation between the conjugate diene-lipid level and 
the time of exposure in the first three hours (r=0.996) (Hrelia et al., 2002). The increase 
in intracellular ceramide, a biomarker of lipid peroxidation, was observed in rat cardiac 
myocyte with one hour treatment of DOX (0.5 μM). The DOX-induced lipid peroxidation 
led to apoptosis after 7-day of the DOX treatment in cardiomyocyte. Lipid peroxidation-
induced apoptosis was prevented in cardiac myocyte with the treatment of L-carnitine 
(200 μg/ml), a compound with protective effect on cardiac metabolism (Andrieu-Abaddie 





Deoxyribonucleic Acid (DNA)  
Damage 
 
Several mechanisms have been proposed for DOX-mediated deoxyribonucleic 
acid (DNA) damage, including topoisomerase inhibition, DNA adduct formation, and 
oxidative stress by ROS (Yang, Teves, Kemp, & Henikoff, 2014). The DOX-induced 
topoisomerase II poisoning has been clinically used to increase double-strand DNA 
breaks, resulting in DNA damage and cell death. Topoisomerase II is an ATP-dependent 
enzyme that binds DNA supercoils and entangled DNA and releases torsional stress 
formed during DNA replication and transcription. Additionally, topoisomerase II is 
important for separating two topologically-linked daughter chromosomes during mitosis, 
and topoisomerase II inhibition prevents healthy cells from dividing into two daughter 
cells resulting in apoptosis (Carpenter & Porter, 2004; Pommier, Leo, Zhang, & 
Marchand, 2010). Doxorubicin-induced topoisomerase II inhibition has a similar 
mechanism as etoposide which traps a topoisomerase II at breakage sites, stabilizes the 
cleavage complex, and impedes DNA resealing (Nitiss, 2009; Wu et al., 2011). In 
primary mouse embryonic fibroblasts (MEF) with DNA topoisomerase II β knockout 
(top2β−/−), the level of DOX-induced γ-H2AX, a key DNA damage signal induced by 
double-strand DNA breaks, reduced in comparison with MEFs with DNA topoisomerase 
IIβ (TOP2β+/+). This study suggests that the DOX mediates DNA damage signal γ-H2AX 
with topoisomerase IIβ (Lyu et al., 2007). 
Additionally, topoisomerase IIβ was mainly involved in DOX-induced heart 
failure, which is a side effect of damaging non-dividing cells. It has been shown that 
TOP2β+/+ cardiomyocytes of mice, injected with 25 mg/kg DOX and harvested 16 hours 




fold. The genes involved in the apoptotic pathway, such as Apaf1, Bax, and Fas, showed 
an upregulation of their transcriptions. The upregulations of pro-apoptotic genes were 
only expressed in DOX-treated TOP2β+/+ mice but not in top2β−/− mice with the same 
DOX treatment (Zhang et al., 2012). These findings suggest that DOX treatment can 
force cardiomyocytes into apoptosis by double-strand DNA breaks utilizing 
topoisomerase IIβ.  
Doxorubicin is also able to cause DNA adduct formation as a DNA intercalator 
and activate DNA damage responses leading to topoisomerase II-independent cell death 
(Chaires, Herrera, & Waring, 1990; Chen, Gresh, & Pullman, 1986; Swift, Rephaeli, 
Nudelman, Phillips, & Cutts, 2006). Doxorubicin is more likely to intercalate at the 
adjacent GC base pairs due to specific hydrogen bond formation between DOX and 
guanine. A covalent bond mediated by formaldehyde, generated by free radical reactions 
from lipids and spermine, plays a primary role to stabilize DOX and DNA interaction. 
This interaction involves DOX forming a covalent bond with guanine on one strand of 
DNA mediated by formaldehyde and hydrogen bonds with guanine on the opposing 
strand (Taatjes, Gaudiano, Resing, & Koch, 1996). In cultured breast cancer cells (MCF-
7), the elevated level of formaldehyde was observed with the highest concentration of 
DOX treatment (50 µM). The DOX sensitive MCF-7 cells had a higher formaldehyde 
count by 16.7 ± 4.3 compared to the DOX-resistant MCF-7 cells (Kato, Burke, Fenick, 
Taatjes, & Bierbaum, 2000). Another DOX-induced DNA adduct experiment was 
performed in the promyelocytic leukemia cell line HL-60 and the mitoxantrone resistant 
variant HL-60/MX2, which has a decreased expression of topoisomerase IIα and no 




adduct formation in the presence of formaldehyde increased from ~2 adducts per 10 kb 
DNA for one µmol/L of DOX to ~8.5 adducts per 10 kb DNA for four µmol/L of DOX. 
The cells were also treated with a combination of DOX (1, 2, and 4 µmol/L) and 
pivaloyloxymethyl butyrate (AN-9, 50 µmol/L), a compound that releases formaldehyde 
upon hydrolysis. The adduct formation with the combination treatment increased DOX 
concentration-dependent apoptosis in both HL-60 and HL-60/MX2 cells, 30-50%, and 
20-50% respectively. The activity level of Caspase-3/7, the executioners in apoptosis, 
was also measured, and the pattern of the activity was matched with the pattern of 
induction of apoptosis by sub-G1 DNA content analysis and by DNA fragmentation. They 
showed that DOX-induced DNA adducts in the formation of formaldehyde could lead to 
a DOX concentration-dependent apoptosis in leukemia cells (Swift et al., 2006). 
Although evidence suggests that DNA damage-induced apoptosis in cancer cells 
and cardiomyocytes by topoisomerase II and DNA adducts with DOX treatments, they 
are unlikely to be the important mechanisms of doxorubicin action. According to Pang et 
al. (2013), human melanoma cells were treated with a standard clinical dosage, 9 µM of 
DOX with inhibition of topoisomerase II and it strongly induced apoptosis which was led 
by histone eviction. Additionally, a clinical dose for DOX (typically >10 µM) causes 
only 4.4 ± 1.0 adduts/107 base pair DNA, and it is a small fraction of total DOX 
(Coldwell, Cutts, Ognibene, Henderson, & Phillips, 2008). 
Further studies were investigated for more mechanisms of DOX-induced DNA 
damage besides the inhibition of topoisomerase II and DNA adduction. A different 
mechanism was found that DOX can also be oxidized into doxorubicin-semiquinone 




synthase (Doroshow, Synold, Somlo, Akman, & Gajewski, 2001). Due to the instability 
of semiquinone radicals, they immediately react with oxygen and produce ROS including 
•O−2 and H2O2 leading to DNA damage (Berlin & Haseltine, 1981; Minotti et al., 2004). 
According to Myers (1998), DOX can bind to metal molecules and form a DOX-iron 
complex. This bond catalyzes H2O2 to ·OH which is a highly reactive molecule. 
Doxorubicin-induced ROS can lead to oxidative stress and result in DNA damage 
and apoptosis (Thorn et al., 2011). In previous studies, researchers suggested that the 
redox cycling of DOX by NADH dehydrogenase induced oxidative stress and led to 
DNA base modifications. Oxidative DNA bases such as thymine glycol and 8-
hydroxyguanine are mutagenic and are produced by ·OH characteristic chemical species 
in human chromatins (Basu, Loechler, Leadon, & Essigmann, 1989; Shibutani, Takeshita, 
& Grollman, 1991). Another study showed that erythrocytes from breast cancer patients 
had a significant increase in DNA base oxidation by DOX-induced ROS after 72 to 96 
hours of intravenous infusion of 1 µM of DOX (p<0.02)  (Doroshow et al., 2001). In 
H9C2 rat cardiomyocytes, the oxidized DNA bases, including 8-hydroxyguanine and 
pyrimidines, were observed and induced the activity of p53 (L'Ecuyer et al., 2006). The 
relationship between oxidative stress and DNA damage were examined in cultured 
cardiomyocyte of rats. With the 1 µM of DOX treatment for four and eight hours, DNA 
damage increased as oxidative stress increased. Also, the accumulation of p53 and 
cleaved caspase-3 expression were detected by western blot assay (p<0.05). The 
apoptotic cell death was also observed after eight hours of DOX treatment. DOX-induced 
oxidative stress and p53 expression were reduced by a free radical scavenger, N-Acetyl-




cardiomyocyte. In the p53 mice model with 6 mg/kg of DOX treatment for four weeks, 
an increased in impaired contractile function and apoptotic cardiomyocytes in p53 wild 
type mice model were detected compared to p53 heterozygous knockout mice (p<0.05). It 
was suggested that p53 accumulation and apoptotic cardiomyocyte were caused by DOX-
induced ROS, resulting in DNA damage (Yoshida et al., 2009).  
In another study, a significantly elevated level of cytosolic cyt c was observed in 
mitochondria of DOX (20 mg/kg) treated cardiomyocytes of rats compared to the control 
group (p=0.033). Also, the positive correlation of cytosolic cyt c and caspase-3 activity 
was found in the DOX-treated group (r=0.88, p=0.003). These findings suggested that the 
in vivo levels of cyt c in the cytoplasm of cardiomyocytes directly affect caspase-3 
activity, which results in apoptosis. The significantly elevated level of 8-iso-PGF2α, a 
marker of oxidative stress to lipids, was detected in the cytosol of rats treated with DOX 
(p=0.036). This result suggests that DOX induces oxidative stress in vivo and leads to an 
elevated cyt c release resulting in apoptosis of cardiomyocyte of rats (Childs, Phaneuf, 
Dirks, Phillips, & Leeuwenburgh, 2002). These DNA base modifications and oxidative 
stress by ROS can promote mutations and impair the functions of replication and 
transcription, resulting in cell death (Jena, 2012). 
Doxorubicin and Skeletal Muscle 
 
The DOX chemotherapy has been associated with myotoxicity in many tissues, 
including cardiac and skeletal muscle. Dorxorubicin-induced skeletal muscle toxicity has 
resulted in an increase in muscle dysfunction, fatigue, and atrophy depending on time and 
injection dosage (Brehdal, Pfannenstiel, Quinn, Hayward, & Hydock, 2016; Hydock et 




deleterious effect of DOX is a serious problem because it directly affects activities of 
daily living (ADL) requiring the utilization of skeletal muscle in cancer patients 
undergoing DOX chemotherapy (Schwartz, 2000). 
 The contractile dysfunction of extensor digitorum longus (EDL) of the mouse was 
observed with DOX treatment (50 – 175 µM) for 0 – 2 hours in ex vivo and in vitro 
assays. Due to the significantly longer relaxation time at 90 – 100% of the maximal force 
in all of the different dosages of DOX (p<0.05), maximal force, contraction and 
relaxation velocity significantly decreased in a time- and dose-dependent manners 
(p<0.05). The slower relaxation velocity is associated with impaired relaxation, which is 
directly related to the rate of calcium (Ca2+) clearance from the cytoplasm. They further 
investigated a calcium influx with oxidative stress, which was applied to C2C12 
myotubes and resulted in producing ROS due to a mitochondrial malfunction. Even 
though the increase in ROS led to cell death in C2C12 cells, the increase in Ca2+ influx 
was not observed (MacLennan, 2000; Van Norren et al., 2009). However, Abramson, 
Buck, Salama, Casida, and Pessah (1988) found evidence that DOX (< 10 µM) induced 
Ca2+ release by 50-60% in rabbit skeletal muscle sarcoplasmic reticulum (SR), which 
stores Ca2+ and regulates contraction and relaxation in skeletal muscle. This study 
suggested that DOX-induced Ca2+ release from SR has a direct dose-dependent 
interaction with the ryanodine receptor (RYR) complex, a calcium release channel, by 
increasing the sensitivity of calcium activator site of RYR. 
 The increase in intracellular Ca2+ release can trigger the caspase cascade and 
calpain, a Ca2+-dependent protease (on caspase protease) involved in apoptosis (Momeni, 




muscle of rats 24 hours before sacrifice activated protease, including calpain and caspase-
3. The ratio of calpain-to-calpastatin (calpain inhibitor) was significantly higher 
compared to the control group without DOX (p<0.05). Also, the expression of cleaved 
caspase-3, often activated by casp-9 in the caspase cascade, was significantly higher than 
the control group in a western blot assay (p<0.05). These results showed that the DOX 
treatment triggered apoptosis via caspase protease and on caspase protease in SOL 
muscle. 
Additionally, one of the contractile proteins of skeletal muscle, actin, was 
observed as a marker of muscle proteolysis. The increase in activity of calpain and 
caspase-3 significantly lowered the actin level in SOL with DOX treatment compared to 
the control group without DOX and the endurance exercise training group without DOX 
treatment (p<0.05). The percentage of myofilament release showed a significant increase 
(p<0.05) in SOL with 20 mg/kg of DOX injection due to the loss of actin leading to 
reduction of skeletal muscle cross-sectional which can cause the contractile dysfunction 
(Smuder et al., 2011). Another study showed that Ca2+-mediated calpain activation 
significantly increased in the diaphragm, plantaris, and soleus of rat model with the 
clinical dosage (20 mg/kg) of DOX injection 48 hours prior to sacrifice. The active 
calpain can cause the release of cyt c and AIF by breaking the bond of cardiolipin and 
inner mitochondrial membrane (Min et al., 2015). Then, the release of cyt c and AIF 
triggers DNA fragmentation and initiates apoptosis in cells.  
 Doxorubicin-induced contractile dysfunction and atrophy can be triggered by a 
large amount of DOX-induced ROS production, leading to oxidative stress in skeletal 




significant increase in mitochondrial ROS emission was detected in the diaphragm, 
plantaris, and soleus muscles with 20 mg/kg of DOX treatment in rats (p<0.05). Besides, 
the mitochondrial-targeted antioxidant, SS31, was utilized with DOX treatment in all 
three tissues, and the DOX-mediated mitochondrial ROS emission was prevented. They 
also observed oxidative damage in muscle proteins triggered by the DOX-mediated 
mitochondrial ROS production. The level of 4-HNE, a biomarker of lipid peroxidation, 
was significantly increased with the DOX treatment (20 mg/kg) compared to the control 
group without the DOX injection (p<0.05). Important to note, the tissues with SS31 
treatment prevented the increase in 4-HNE, indicating that the DOX-mediated 
mitochondrial ROS emission resulted in oxidative stress in the skeletal muscle, causing 
lipid peroxidation. The increase in mitochondrial ROS emission by the DOX treatment in 
diaphragm led to a significant reduction in diaphragmatic specific force production 
compared to the control group. Additionally, there was a significant decrease in myofiber 
cross-section area (CSA) in all three skeletal muscles including the diaphragm, plantaris 
and soleus muscles (p<0.05), however, the reduction in myofiber CSA was protected 
with the antioxidant treatment of SS31 in these tissues. This indicated that DOX-induced 
mitochondrial ROS caused contractile dysfunction and skeletal muscle atrophy. 
Interestingly, cardiolipin, the anchorage protein for AIF and inner mitochondria 
membrane, can also be readily peroxidized in ROS-induced oxidative environment and 
promote the opening of MPT leading to release of AIF including cyt c besides the 
mechanism that the Ca2+-mediated calpain activation dephosphorylates cardiolipin 
(Montaigne et al., 2011). Therefore, DOX treatment induces mitochondrial ROS 




MPT pores by ROS-mediated cardiolipin dephosphorylation causing the release of AIF 
from the mitochondria. 
Doxorubicin-induced mitochondrial ROS production can also upregulate the 
muscle regulatory proteins, causing muscle degradation in skeletal muscle. For example, 
E3 ubiquitin ligases, including atrogin-1/MAFbx and MuRF1, are mainly involved in 
muscle protein degradation. The upregulation of these proteins can be found in many 
catabolic situations such as inflammation and starvation (Dogra et al., 2007; Jagoe, 
Lecker, Gomes, & Goldberg, 2002). Evidence showed that the exposure of 0.2 µM DOX 
to C2C12 myotube led to a significantly increased level of atrogin-1/MAFbx mRNA, 
along with a rise in protein 24 hours after the exposure (p<0.05). However, DOX 
treatment in C2C12 myotubes altered neither of the levels of MuRF1 mRNA or MuRF1 
protein level. To ensure the increase in atrogin-1/MAFbx mRNA and protein levels was 
affected by the DOX-induced mitochondrial ROS emission, C2C12 was treated with the 
mitochondrial-targeted antioxidant, SS31. The level of atrogin-1/MAFbx mRNA was 
reduced with the SS31 treatment and the decrease in myotube width and the loss of 
contractile proteins including myosin and actin, caused by DOX treatment, were 
prevented as well (Gilliam et al., 2012).  
These previous studies showed that the DOX treatment induced apoptosis via 
activating Ca2+-mediated calpain leading to the increase in the opening of MPT pores in 
mitochondria which released AIF including cyt c to the cytoplasm. In addition, DOX-
induced mitochondrial ROS production could increase the level of MPT pores by lipid 




involved in muscle protein degradation such as atrogin-1/MAFbx. The DOX-mediated 
apoptosis in skeletal muscle leads to contractile dysfunction and muscle atrophy. 
Creatine 
 
Creatine (Cr) is an organic compound that is endogenously synthesized with two 
amino acids, arginine, and glycine, that are combined by the enzyme arginine:glycine 
amidinotransferase (AGAT). The combination of arginine and glycine forms 
guanidinoacetate which is methylated with S-adenosyl methionine by guanidinoacetate 
N-methyltransferase, leading to the formation of Cr. The synthesis of Cr primarily occurs 
in the liver and is transported to other organs that store and utilize Cr through the blood. 
By utilizing its concentration gradient, Cr is diffused and transported through sodium and 
chloride dependent transporter into tissues from the blood. Most of Cr (95% of total Cr) 
becomes stored in skeletal muscle while the remaining 5% of the Cr can be found in the 
blood, brain, liver, and kidney. In addition, Cr can also be obtained by dietary intake, and 
the average Cr uptake from the diet is ~1g/day in young adults (Walker, 1979). 
 Creatine kinase (CK) can convert Cr and ATP to phosphocreatine (PCr) and 
adenosine diphosphate (ADP). PCr can be seen as an energy buffer in the PCr energy 
system because it can form ATP and Cr through the reversible reaction of CK. This 
reversible reaction of PCr plays an essential role in rapid ATP production during high-
intensity, short duration (~10 seconds) exercises such as sprints and repeated bouts of 
maximum weight lifting. The formation of ATP and Cr from PCr becomes favored due to 
the low pH level caused by the rapid accumulation of lactic acid produced by high-
intensity anaerobic exercise (Demant & Rhodes, 1999; Walker, 1979; Yquel, Arsac, 




concentration from 19 to 32 mM in rat SOL and extensor digitorum longus (EDL) 
muscles increased the maximum Ca2+-activated force by 104 ± 1 and 105 ± 1%, 
respectively, by increasing Ca2+ sensitivity in skeletal muscle. This study suggested that 
an increase in Cr concentration resulted in increased maximum force in skeletal muscle 
(Murphy, Stephenson, & Lamb, 2004).  
 Creatine monohydrate supplementation is well known to facilitate in increasing 
total Cr concentration in muscles. The ingestion of 20g of creatine monohydrate 
supplement for five days increased the muscle total Cr concentration and PCr 
concentration by 18% and 10%, respectively (Casey, Constantin-Teodosiu, Howell, 
Hultman, & Greenhaff, 1996). Another study showed a similar result with the intake of 
20 to 30g of creatine monohydrate per day for two days significantly increasing total Cr 
concentration by 20 to 40%  in the quadriceps femoris muscles of 17 healthy participants. 
This increase in total muscle Cr concentration can enhance performance and decrease 
fatigue during anaerobic exercise (Harris, Söderlund, & Hultman, 1992). In Hultman, 
Söderlund, Timmons, Cederblad, and Greenhaff study (1996), the effects of creatine 
loading treatment was also investigated in vastus lateralis muscle of health men. The 
group with 20 g/day Cr supplements for six days followed by 2 g/day for the next 28 days 
had a rapid increase in total Cr concentration by ~16 mmol/kg dry mass after 6-day of the 
20 g/day Cr consumption. The Cr loading group maintained the elevated total Cr 
concentration in vastus lateralis muscle after 28-day when the group without the Cr 
loading protocol declined its total Cr concentration (p<0.05). 
 Many researchers have shown that the effect of the creatine monohydrate 




per day for six days) significantly increased the volume of the 1-rep max (RM) deadlift 
compared to the placebo group without the Cr supplementation (p=0.010) (F. Rossouw, 
Kruger, & J. Rossouw, 2000). Nine weeks of Cr supplementation (20g per day for five 
days followed by 5g per day for the rest of days) with a strength training program showed 
an improvement in exercise performance in collegiate football players (M. Bemben et al., 
2001). The Cr supplement group showed significant increases in body weight and lean 
body mass post Cr supplement consumption (p<0.05). Also, anaerobic strength improved 
in all three lifts, including bench press, power clean, and squat by 5.2%, 3.8%, and 8.7%, 
respectively. In addition, the Wingate bicycle ergometer test was performed to measure 
anaerobic power and capacity, and the Cr group improved in both anaerobic power and 
anaerobic capacity by 19.6% and 18.4%, respectively (M. Bemben et al., 2001). The 
improvement in exercise performance with Cr supplementation also was shown in sprint 
performance. The intake of 5g Cr supplement for five days significantly increased body 
weight in professional male sprinters compared to pre-Cr supplement consumption 
(p<0.05). The participants in the Cr group showed a significant decrease in 100 m sprint 
time from 11.68 seconds to 11.59 seconds (p<0.02) (Skare et al., 2001).  
Creatine monohydrate supplementation also showed the effect in myofibrillar 
protein and myosin heavy chain (MHC) protein with resistance training for six months. 
Total body mass and strength significantly increased in the Cr supplementation group 
compared to the control group and the placebo group only with the resistance training 
(p<0.05). Additionally, the myofibrillar protein expression and the MHC protein 
expression increased by 57.92% and 17.49%, respectively, in the Cr supplement group 




exercise training enhances the power, strength, and speed by delaying fatigue and 
increasing the muscle protein expression. 
 Although many studies have focused on the improvement of exercise performance 
with the Cr supplement, recent investigations have proposed the antioxidant effect of Cr 
in the oxidative environment. Lawler et al. (2002) investigated the association between 
antioxidant scavenging capacity (SAC) and creatine. In a dose-dependent manner, a 
significant relationship between SAC and Cr concentration was found (r=0.88), which 
indicated the direct antioxidant capacity of Cr. The antioxidant effect of Cr only affected 
on •O−2 and peroxynitrite (OONO
−) in this study. The treatment with 40 mM Cr resulted 
in a significant increase in quenching •O−2 compared to the control group. The SOD 
equivalent units of •O−2 quenching in the control group and Cr group were 4 ± 9 and 68.0 
± 32.5, respectively. A similar result was shown in H2O2 quenching with 40 mM Cr; 
however, the significant difference was not observed between the control and Cr groups. 
The OONO− quenching also significantly increased in a dose-dependent manner, and the 
most effective Cr concentration of the removal of OONO− was found to be at 60 mM Cr. 
These results indicate that Cr possesses the direct antioxidant capacity in the removal of 
•O−2 and OONO
−. The formation of Cr with arginine can explain the ability of Cr to 
scavenge free radicals. Arginine has an antioxidant capacity by quenching •O−2, generated 
by xanthine oxidase or released from endothelial cells. Since Cr is synthesized with 
arginine and glycine, the study suggests that the antioxidant effect of arginine may be 
possessed in Cr as well (Lawler et al., 2002). 
 In Guimarães-Ferreira et al. (2012) study, H2O2 production significantly 




The SOL and EDL were treated with 5 g/kg creatine for six days. The percent change of 
H2O2 compared to the control group without Cr treatment in SOL and EDL muscles were 
59 % and 76.3%, respectively. Creatine supplementation in SOL and EDL did not affect 
the level of antioxidant enzyme mRNA including the primers for SOD, mitochondrial 
manganese SOD, and catalase indicating the direct antioxidant capacity of Cr.  
Another study performed investigated the antioxidant capacity of Cr with acute 
exercise training in rats. The acute exercise training group with a 2% creatine 
monohydrate diet for 28 days had a significant increase in total muscle Cr concentration 
(p<0.05) compared to the control group that did not receive the Cr diet. Plasma 
thiobarbituric acid reactive species (TBARS), a byproduct of lipid peroxidation, and total 
lipid hydroperoxide were observed as markers for oxidative stress-induced ROS in 
skeletal muscle. In SOL and gastrocnemius muscles with the Cr diet, the level of TBARS 
decreased by 20% after six hours and total lipid hydroperoxide level also decreased by 
20% after six hours. These results indicated that the 2% Cr monohydrate diet directly 
facilitated the antioxidant activity in increased oxidative stress markers caused by acute 
exercise (Deminice & Jordao, 2012). 
An excessive ROS production in skeletal muscle is one of many mechanisms that 
trigger apoptosis via mitochondrial dysfunction in skeletal muscle. According to Ceddia 
and Sweeney (2004), 5’ adenosine monophosphate-activated protein kinase (AMPK) 
signaling plays a key role in ROS-induced mitochondrial dysfunction/impairment, muscle 
atrophy, and sarcopenia, a loss of muscle mass. It has been suggested that Cr supplement 
increased in the activity of AMPK via glucose oxidation. The production of 14CO2, 




myoblasts treated with 0.5 mM Cr, the basal production of 14CO2 significantly increased 
by 1.4-fold compared to the control group without the Cr treatment (p<0.05). AMP 
kinase activity was measured, and the significant increase in AMPK activity was 
observed with a ~2.2-fold increase (p<0.05). This study suggested that the increased 
activation of AMPK activity with Cr treatment might prevent mitochondrial dysfunction. 
However, it was unknown if AMPK activity also increased in oxidative damaged skeletal 
muscle. 
 Even though the exact mechanism of Cr supplementation preventing ROS-
induced apoptosis is not known, the Cr supplement has shown to prevent apoptosis in 
ischemic cells via activating the anti-apoptotic pathway. The H9c2 cardiomyocytes 
treated with 0.5 µM of DOX, significantly decreased the cell viability by 35% (p<0.001). 
The Cr treatments (2.5 mM Cr, 5 mM Cr, and 10 mM Cr) significantly increased 
compared to the only DOX treated cell in a dose-dependent manner (p<0.05). The 50.4% 
decreased cell viability was also observed in ischemic cardiomyocytes, restricted with 
blood supply, compared to the control group (p<0.001). Unlike the DOX treated cells, the 
2.5 mM Cr treatment did not increase the cell viability; however, the combination of 5 
mM ribose and 2.5 mM Cr significantly improved cell viability by 30% (p<0.01). The 
apoptotic enzymes, cleaved caspase-3 and poly ADP-ribose polymerase (PARP), were 
observed in control, Cr and, ribose treated ischemic H9c2 cells. The Cr and ribose 
treatment significantly reduced the protein expressions of cleaved caspase-3 and PARP 
compared to the untreated ischemic cell (p<0.5). The increased activation of Akt 
pathway, known as an anti-apoptotic pathway, was observed in Cr and ribose treated 




supplementation could activate the anti-apoptotic pathway and prevent apoptosis in DOX 
treated and ischemic cardiomyocytes. However, the antioxidant effects of Cr supplement 
treatment were not found to prevent DOX-induced apoptosis in cardiomyocytes (Caretti 
et al., 2010).  
Conclusion 
 
DOX is a highly effective chemotherapeutic drug used in many types of cancer. 
Due to its structure, DOX often goes into redox cycling with NAD(P)H and induces the 
release of ROS, leading to lipid peroxidation, DNA damage, and oxidative stress in cells 
(Doroshow, 1986; Gewirtz, 1999). The usage of DOX in the clinic has been limited 
because the excessive release of ROS results in toxicities and triggers apoptosis in many 
tissues, including heart and skeletal muscle (Minotti et al., 2004). The contractile 
dysfunction, including maximal force, contraction, and relaxation velocity, is induced by 
DOX treatment, which increases mitochondrial ROS production. Doxorubicin-induced 
apoptosis in skeletal muscle is initiated via the opening of MPT pores which often is 
induced by Ca2+-mediated mitochondrial swelling, the excessive release of the 
mitochondrial ROS production, and activation of calpain which releases AIF including 
cyt c into cytoplasm (Min et al., 2015; Smuder et al., 2011; Van Norren et al., 2009). 
 The release of cyt c from mitochondria is a biomarker for the initiation of 
apoptosis. The mitochondrial ROS production causes DNA damage and lipid 
peroxidation, which damages the inner mitochondrial membrane. The damage of the 
membrane in mitochondria breaks the bond between cardiolipin and cyt c, leading to the 
release of cyt c. Additionally, ROS production induces the proapoptotic Bcl-2 family 




the cytoplasm from mitochondria. The formation of apoptosome with Apaf-1 and cyt c 
cleaves procaspase-9 and initiates the apoptotic caspase-cascade, resulting in apoptosis 
(Cory & Adams, 2002; Saelens et al., 2004). The regulation of apoptosis is critical in 
skeletal muscles because the decreased in muscle contractile proteins results in 
contractile dysfunction and muscle atrophy (Gilliam et al., 2012; Min et al., 2015). 
 Creatine is an organic compound, primarily synthesized in the liver and obtained 
by the diet. The ergogenic capacity of Cr via the PCr energy system has shown with the 
reversible reaction of CK. The rapid production of ATP from PCr and ADP occurs during 
high-intensity, and short duration exercises that lowers the pH and favors the formation 
of Cr and ATP. Creatine supplementation increases total muscle Cr concentration in 
skeletal muscle and improves exercise performance by delaying fatigue and increasing 
contractile muscle proteins with exercise training (Cory & Adams, 2002; Saelens et al., 
2004).  
 Besides the positive effect of Cr on exercise performance, some researchers 
suggest a direct antioxidant capacity of Cr. The ability to quench ROS,  •O−2, and 
OONO−, has shown (Lawler et al., 2002). Additionally, decreased levels of  H2O2, 
TBARS, and lipid hydroperoxide has been observed with Cr supplementation and 
exercise training in skeletal muscles (Deminice & Jordao, 2012; Guimarães-Ferreira et 
al., 2012). Creatine supplementation possibly prevents ROS-induced mitochondrial 
dysfunction and apoptosis via activation of the AMPK pathway and reduces apoptotic 
enzyme activities by activating the anti-apoptotic Akt pathway (Ceddia & Sweeney, 




 In summary, DOX is a highly effective therapeutic drug for many types of 
cancers; however, its clinical usage is limited due to producing an excessive amount of 
ROS in heart and skeletal muscles during the process of its metabolism. The DOX-
induced ROS release in mitochondria leads to lipid peroxidation, DNA damage, and 
oxidative stress triggering apoptosis in cells. The apoptosis is initiated by initiator 
apoptotic enzymes, cyt c and casp-9. Doxorubicin-induced mitochondrial ROS 
production releases cyt c into cytoplasm and activates casp-9 leading to apoptosis. 
Doxorubicin-induced apoptosis is critical in skeletal muscles because it results in 
contractile dysfunction and muscle atrophy. Recent findings have suggested that Cr 
supplement reduces mitochondrial ROS production and potentially prevents initiation of 
apoptosis in skeletal muscles with its direct antioxidant effect; however, its exact 
mechanism is not yet fully understood. 
This study demonstrates the potential intervention for preventing the initiation of 
apoptosis caused by DOX-induced ROS production in mitochondria with creatine 
supplementation. As previous literatures mentioned, the antioxidant capacity of creatine 
should reduce apoptosis, which is initiated by DOX-induced ROS production and 












All the procedures were approved by University of Northern Colorado 
Institutional Animal Use and Care Committee and followed the Animal Welfare Act. 
Ten-week-old male Sprague Dawley rats (Envigo, Indianapolis, IN, N=120) were 
individually housed and maintained on a 12:12 hour light-dark cycle at normal room 
temperature and humidity. Rats were provided with rodent chow and water ad libitum. 
They were randomly divided into three groups: normal chow (CON, n=40), 2% creatine 
chow (2% Cr, n=40), and the creatine loading diet consisting of one week of 4% creatine 
chow followed by three weeks of 2% creatine chow (4% Cr, n=40). Each group was then, 
again, randomly assigned into two groups which included 1-day injection prior to 
sacrifice (1, n=20) and 3-day injection prior to sacrifice (3, n=20). Lastly, each group was 
randomly divided into two groups: doxorubicin (DOX, n=10) and saline (SAL, n=10). 
The treatments for the groups are shown in figure 1. The 2% Cr groups were provided 
with chow that contained 2% creatine (Sigma-Aldrich, St.Louis, MO) for four weeks, 
while the 4% Cr groups were provided with 4% creatine chow (Sigma-Aldrich, St.Louis, 




mass (g) for all animals were measured once a week during the four-week nutritional 
intervention and prior to sacrifice. 
Figure 1. Experimental Design of Diet Treatments for Groups. 
Drug Treatment 
 
DOX-1 and SAL-1 were injected with 15 mg/kg body weight of DOX 
hydrochloride (Bedford Labs, Bedford, OH) and 3 mL of SAL, respectively, one day 
prior to sacrifice. DOX-3 and SAL-3 were also injected with DOX 15 mg/kg body weight 























































Extensor Digitorum Longus and  
Soleus Preparation 
 
At the determined point, each animal was injected with sodium pentobarbitol (50 
mg/kg) in the lower left abdominal region prior to sacrifice. The tail was pinched to 
ensure the absence of a tail-pinch reflex indicating no pain or discomfort. The left 
extensor digitorum longus (EDL) and left soleus (SOL) were removed, weighed, and 
flash frozen in liquid nitrogen. All tissues were stored in a laboratory freezer at -80°C 
until biochemical analysis. 
Homogenate Preparation 
Frozen portions of the EDL and SOL between 0.07 g and 0.1 g were used for 
homogenization. Muscle samples were manually homogenized with 
radioimmunoprecipitation assay (RIPA, SigmaAldrich: St. Louis, MO) buffer (1:10 tissue 
mass:volume) and 10 µL of protease enzyme inhibitor (SigmaAldrich: St. Louis, MO) in 
a glass tissue homogenizer. Cell membranes were further disrupted with a sonicator 
(Sonic disembrator model 100, Fisher Scientific, Hampton, NH) with ten, one second 
pulses. Samples were then transferred to centrifuge tubes and centrifuged for ten minutes 
at 10,000g. The supernatant was collected, and total protein concentration analyzed using 
the Bradford (Bradford, 1976). Protein concentration was standardized with RIPA buffer, 







Electrophoresis was conducted to separate proteins by molecular weight (kDa) 
using an Xcell II blot module (Invitrogen, LifeTechnologies) on 4-20% gradient Tris-
Glycine precast gels (LifeTechnologies, Carlsbad, CA). Before loading onto gels, 
samples were heated in boiling water for two minutes and transferred to an ice bucket for 
ten minutes. Gels were placed and locked in the Xcell II blot module and the middle 
section was filled with running buffer (100 mL Tris-Glycine Running Buffer (10X): 900 
mL deionized (DI) water). Each 15 µL of sample was loaded on to gels, and 10 µL of 
SeeBlue®Plus2 protein ladder (Novex, LifeTechnologies) and 10 µL of MagicMark™ 
XP standard ladder (Novex, Lifetechnologies) were also loaded on the gels as standards. 
The outside of the chamber was also filled with Tris-glycine running buffer. Gels were 
run at 125 V and 0.04 A until proteins migrated to the bottom of gels.  
Proteins were transferred to a polyvinylidene fluoride (PVDF) membrane (Novex, 
LifeTechnologies) with two filter papers soaked in transfer buffer (40 mL Tris-Glycine 
transfer buffer, 200 mL methanol, and 760 mL DI water). The soaked membranes, filter 
papers, and pads were stacked in the following order: 1) two soaked pads on the bottom 
2) one filter paper 3) gel-1 4) membrane 5) one filter paper 6) one soaked pad 7) filter 
paper 8) gel-2 9) membrane 10) filter paper 11) two soaked pads. The soaked membranes 
were rolled with glass pipette to remove air bubbles between the gels and the transfer 
buffer was poured into the middle of chamber, and DI water filled the outside of the 
chamber. The protein transfer was run for 90 minutes at 25 mV and 0.10 A. Once 
proteins were transferred onto the membranes, the membranes were washed with 20 mL 




blocking buffer (Thermoscientific, Rockford, IL) for thirty minutes using a laboratory 
rocker. PVDF membranes were rinsed again with 20 mL of DI water for five minutes, 
four times. 
The membranes were incubated for 15 – 18 hours with 10 mL of mouse 
monoclonal primary antibodies for cytochrome c (1:200, Santa Cruz Biotechnology: 
Dallas, TX) or cleaved caspase-9 (1:200, Santa Cruz Biotechnology: Dallas, TX). The 
mouse monoclonal antibody GAPDH (1:500, Santa Cruz: Dallas, TX) was used as the 
loading control. PVDF membranes were washed with 20 mL of TBST for five minutes 
and repeated four times and rinsed with 20 mL of DI water for five minutes, twice. 
Membranes were incubated in 10 mL of anti-mouse secondary antibody (1:1000, Santa 
Cruz: Dallas, TX) for one hour. Membranes were again washed with 20 mL of TBST for 
five minutes, four times and then were rinsed with 20 mL of DI water for five minutes, 
twice.  
Protein imaging was completed using enhanced chemoluminescence (ECL) (C-
Digit, Li-Cor, Lincoln, NE), and protein expression was quantified by ImageJ software 
(NIH, Bethesda, MD). 750 mL of luminol and enhancer (C-Digit, Li-Cor: Lincoln, NE) 
were added to the membrane and allowed to incubate for five minutes. Standard 
sensitivity was used at first then if the image was not detected clear, high sensitivity was 
used.   
Statistical Analysis 
Data were analyzed using GraphPad and presented as mean±standard error of the 
mean (SEM). Outliers above or below two standard deviations (SD) from the mean were 




effects of Cr (diet) and DOX (drug) along with diet and drug interactions in cytochrome c 
and cleaved caspase-9 protein expression. Tukey’s post hoc testing was performed if 
there were significant main effects of interactions to identify where differences existed. 











The purpose of this study was to exam in the effects of the two different 
treatments of Cr supplementation on cytochrome c and caspase-9 protein expressions in 
SOL and EDL from rats administered DOX injections at two different time points. Prior 
to sacrifice, five rats did not survive (two from 4% Cr-DOX-1, one from 4% Cr-SAL-3, 
and two from 4% Cr-DOX-3). 
Biochemical Analysis 
 
The 1-SOL, 1-EDL, 3-SOL, and 3-EDL were analyzed to determine the effects of 
two different Cr treatments (2% Cr for four weeks and the Cr loading consisting of 4% Cr 
for one week followed by 2% Cr for three-week) and DOX administration at 1-day and 3-
days prior to sacrifice on the protein expressions of cyt c and casp-9. Protein expression 
was expressed relative to the expression of mouse monoclonal antibody GAPDH as the 
loading control. Cytochrome c expression is shown in Table 1 (1-SOL and 3-SOL) and 
Table 2 (1-EDL and 3-EDL), and casp-9 expression is shown in Table 3 (1-SOL and 3-










Cyt c Western Blot expressions 
 
Muscle CON-SAL CON-DOX 2% Cr-SAL 2% Cr-DOX 4% Cr-SAL 4% Cr- DOX 
1-SOL 0.31 ± 0.03 0.37 ± 0.06 0.34 ± 0.03 0.39 ± 0.03 0.49 ± 0.05 0.40 ± 0.03 
3-SOL 0.30 ± 0.03 0.48 ± 0.11 0.49 ± 0.04 0.60 ± 0.09 0.34 ± 0.06 0.44 ± 0.10 
Note. Cyt c= cytochrome c, 1-SOL= one-day soleus, 3-SOL = three-day soleus, CON-
SAL = control diet saline, n=10, n=8, CON-DOX = control diet doxorubicin, n=9, n=10, 
2% Cr-SAL = 2% creatine diet saline, n=8, n=8, 2% Cr-DOX = 2% creatine diet 
doxorubicin, n=8, n=10, 4% Cr-SAL = creatine loading saline, n=10, n=8, 4% Cr-DOX 
= creatine loading doxorubicin, n=8, n=9. Values are means ± SEM.  
 
Table 2 
Cyt c Western Blot expressions 
 
Muscle CON-SAL CON-DOX 2% Cr-SAL 2% Cr-DOX 4% Cr-SAL 4% Cr- DOX 
1-EDL 0.24 ± 0.10 0.41 ± 0.15 0.41 ± 0.14 0.35 ± 0.11 0.27 ± 0.11 0.39 ± 0.15 
3-EDL 0.56 ± 0.13 0.63 ± 0.14 0.69 ± 0.16 0.54 ± 0.13 0.60 ± 0.15 0.61 ± 0.05 
Note. Cyt c= cytochrome c, 1-EDL= one-day extensor digitorum longus, 3-EDL = three-
day extensor digitorum longus, CON-SAL = control diet saline, n=10, n=10, CON-DOX 
= control diet doxorubicin, n=10, n=10, 2% Cr-SAL = 2% creatine diet saline, n=10, 
n=10, 2% Cr-DOX = 2% creatine diet doxorubicin, n=10, n=9, 4% Cr-SAL = creatine 
loading saline, n=10, n=10, 4% Cr-DOX = creatine loading doxorubicin, n=8, n=7. 
Values are means ± SEM. 
 
Table 3 
Casp-9 Western Blot expressions 
 
Muscle CON-SAL CON-DOX 2% Cr-SAL 2% Cr-DOX 4% Cr-SAL 4% Cr- DOX 
1-SOL 0.69 ± 0.05 0.69 ± 0.06 0.66 ± 0.07 0.79 ± 0.09 0.91 ± 0.11 0.89 ±0.10 
3-SOL 0.65 ± 0.15 0.82 ± 0.14 0.81 ± 0.10 0.98 ± 0.14 1.00 ± 0.16 1.03 ± 0.23 
Note. Casp-9= caspase-9, 1-SOL= one-day soleus, 3-SOL = three-day soleus, CON-SAL 
= control diet saline, n=9, n=10, CON-DOX = control diet doxorubicin, n=9, n=10, 2% 
Cr-SAL = 2% creatine diet saline, n=8, n=9, 2% Cr-DOX = 2% creatine diet 
doxorubicin, n=10, n=10, 4% Cr-SAL = creatine loading saline, n=10, n=9, 4% Cr-DOX 














Casp-9 Western Blot expressions 
 
Muscle CON-SAL CON-DOX 2% Cr-SAL 2% Cr-DOX 4% Cr-SAL 4% Cr- DOX 
1-EDL 0.05 ± 0.01 0.06 ± 0.01 0.07 ± 0.02 0.09 ± 0.02 0.09 ± 0.02 0.06 ± 0.01 
3-EDL 0.06 ± 0.01 0.07 ± 0.01 0.07 ± 0.02 0.06 ± 0.02 0.08 ± 0.02 0.10 ± 0.02 
Note. Casp-9= caspase-9, 1-EDL= one-day extensor digitorum longus, 3-EDL = three-
day extensor digitorum longus, CON-SAL = control diet saline, n=10, n=7, CON-DOX 
= control diet doxorubicin, n=10, n=9, 2% Cr-SAL = 2% creatine diet saline, n=8, n=9, 
2% Cr-DOX = 2% creatine diet doxorubicin, n=10, n=8, 4% Cr-SAL = creatine loading 
saline, n=10, n=8, 4% Cr-DOX = creatine loading doxorubicin, n=6, n=6. Values are 




 The protein expression of cyt c was measured to see if there was an initiation of 
apoptosis with the effects of Cr supplementation and DOX administration. In the 1-SOL, 
no significant effects of the Cr supplementation (p=0.08) and the DOX injection (p=0.85) 
were observed. The interaction between the Cr supplementation and the DOX injection 
was not significant (p=0.17). The cyt c expression, however, in the CON-DOX increased 
by 19.4% compared to the CON-SAL group. 2% Cr-DOX showed an increase of 14.7% 
from the 2% Cr-SAL group while there was a 18.4% decrease of cyt c expression in the 
4% Cr-DOX group compared to 4%-Cr SAL (Figure 2). There were no significant effects 
of the Cr diet treatments (p=0.10) and the DOX administration (p=0.09) in the 3-SOL. No 
significant interaction between the Cr diet treatments and the DOX administration was 
observed (p=0.87). In the CON groups, DOX increased the expression of cyt c by 60%. 
There was a 22.4% increase in 2% Cr-DOX compared to 2% Cr-SAL. DOX also 






















                                                                       
 
 
Figure 2. Cyt c expression in 1-SOL. 
Cyt c= cytochrome c (15 kDa), GAPDH= loading control, 1-SOL= one-day soleus, SAL= 
saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% creatine diet, 4%= creatine 
loading; control diet saline, n=10, control diet doxorubicin, n=9, 2% creatine diet saline, 
n=8, 2% creatine diet doxorubicin, n=8, creatine loading saline, n=10, creatine loading 







































































                                                                     
  
  
Figure 3. Cyt c expression in 3-SOL. 
Cyt c= cytochrome c (15 kDa), GAPDH= loading control, 3-SOL= three-day soleus, 
SAL= saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% creatine diet, 4%= 
creatine loading; control diet saline, n=8, control diet doxorubicin, n=10, 2% creatine 
diet saline, n=8, 2% creatine diet doxorubicin, n=10, creatine loading saline, n=8, 
creatine loading doxorubicin, n=9. Values are mean ± SEM. 
 





















































 In the 1-EDL, the effects of the Cr diet treatments and the DOX administration 
were not significant (p=0.89 and p=0.46, respectively). There was no significant 
interaction with the Cr supplementation and the DOX injection (p=0.63). Doxorubicin 
administration increased cyt c expression by 70.8% in the CON group. A 14.6% decrease 
was observed in the 2% Cr-DOX compared to the 2% Cr-SAL group while the 
expression of cyt c increased by 30.8% in the 4% Cr-DOX group compared to the 4% Cr-
SAL group (Figure 4). In the 3-EDL, there was no significant effects of the Cr 
supplementation observed (p=0.99). The DOX injection showed no significant effect 
either (p=0.84). The interaction between the Cr diet treatments and the DOX injection 
was not significant (p=0.71). Cytochrome c expression had a 12.5% increase in the CON-
DOX group compared to the CON-SAL group. The DOX administration decreased the 
protein expression by 21.7% in the 2% Cr group. There was a 1.7% increased expression 


























                                                                    
 
  
Figure 4. Cyt c expression in 1-EDL. 
Cyt c= cytochrome c (15 kDa), 3-EDL= one-day extensor digitorum longus, SAL= 
saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% creatine diet, 4%= creatine 
loading; control diet saline, n=10, control diet doxorubicin, n=10, 2% creatine diet 
saline, n=10, 2% creatine diet doxorubicin, n=10, creatine loading saline, n=10, creatine 









































































                                                                      
 
 
Figure 5. Cyt c expression in 3-EDL. 
Cyt c= cytochrome c (15 kDa), GAPDH= loading control, 3-EDL= three-day extensor 
digitorum longus, SAL= saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% 
creatine diet, 4%= creatine loading; control diet saline, n=10, control diet doxorubicin, 
n=10, 2% creatine diet saline, n=10, 2% creatine diet doxorubicin, n=9, creatine loading 



























































 The casp-9 expression was examined to see the initiation of caspase cascade-
mediated apoptosis. There were no significant effects of the Cr supplementation and the 
DOX administration (p=0.63 and p=0.09, respectively). The interaction between the Cr 
supplementation and the DOX administration was not significant (p=0.68). In the 1-SOL, 
the expression of casp-9 of the CON group remained the same with the DOX injection. 
The 2% Cr-DOX had a 19.7% increase compared to the 2% Cr-DOX group. The DOX 
injection decreased the protein expression of casp-9 by 2.2% in 4% Cr-DOX group 
compared to the 4% Cr-SAL (Figure 6). No significant effects of the Cr diet treatment 
and the DOX injection were observed in the 3-SOL (p=0.21 and p=0.34, respectively). 
No significant interaction was observed with the Cr diet treatment and the DOX 
administration (p=0.88). The DOX administration in all three Cr diet groups (CON, 2% 
Cr, and 4% Cr) increased the casp-9 expression by 26.2%, 21.0%, and 3%, respectively, 
























                                                                     
 
 
Figure 6. Casp-9 expression in 1-SOL. 
Casp-9= caspase-9 (35 kDa), GAPDH= loading control, 1-SOL= one-day soleus, SAL= 
saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% creatine diet, 4%= creatine 
loading; control diet saline, n=9, control diet doxorubicin, n=9, 2% creatine diet saline, 
n=8, 2% creatine diet doxorubicin, n=10, creatine loading saline, n=10, creatine loading 







































































                                                                 
 
 
Figure 7. Casp-9 expression in 3-SOL. 
Casp-9= caspase-9 (35 kDa), GAPDH= loading control, 3-SOL= three-day soleus, SAL= 
saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% creatine diet, 4%= creatine 
loading; control diet saline, n=10, control diet doxorubicin, n=10, 2% creatine diet 
saline, n=9, 2% creatine diet doxorubicin, n=10, creatine loading saline, n=9, creatine 
























































 In the 1-EDL, no significant effects were observed in the Cr diet treatments 
(p=0.13) and the DOX administration (p=0.21). The interaction with the Cr 
supplementation and the DOX injection was also not significant (p=0.27). The DOX 
injection increased the protein expression of casp-9 in the CON and 2% Cr groups by 
20.0% and 28.6%, respectively. However, the 4% Cr-DOX group had a 33.3% decrease 
compared to the 4% Cr-SAL (Figure 8). In the 3-EDL, there were no significant effects in 
the Cr supplementation (p=0.10) and the DOX administration(p=0.54). The interaction 
between the Cr diet treatment and the DOX injection was not significant (p=0.51). A 16% 
increase was measured in the CON-DOX group compared to the CON-SAL. The DOX 
administration in the 2% Cr group decreased the casp-9 expression by 14.3% while the 





























                                                                       
 
 
Figure 8. Casp-9 expression in 1-EDL. 
Casp-9= caspase-9 (35 kDa), GAPDH= loading control, 1-EDL= one-day extensor 
digitorum longus, SAL= saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% 
creatine diet, 4%= creatine loading; control diet saline, n=10, control diet doxorubicin, 
n=10, 2% creatine diet saline, n=8, 2% creatine diet doxorubicin, n=10, creatine loading 







































































                                                                   
 
 
 Figure 9. Casp-9 expression in 3-EDL. 
Casp-9= caspase-9 (35 kDa), GAPDH= loading control, 3-EDL= one-day extensor 
digitorum longus, SAL= saline, DOX= doxorubicin, CON= control diet, 2% Cr= 2% 
creatine diet, 4%= creatine loading; control diet saline, n=7, control diet doxorubicin, 
n=9, 2% creatine diet saline, n=9, 2% creatine diet doxorubicin, n=8, creatine loading 



























































The main purpose of this study was to determine changes of the initiator apoptotic 
enzyme expressions cyt c and casp-9 in type I and type II skeletal muscles treated with 
two different Cr supplement treatments and two different time points of DOX 
administrations. In addition, the interaction between the Cr supplementation and the 
DOX administration was examined in this study. The results showed no significant 
effects of the Cr supplementations and the DOX injections on cyt c and casp-9 in both the 
SOL and EDL. No significant interaction was observed between the Cr diet treatment and 
the DOX administration.  
 Even though the results did not indicate significant effects of Cr supplementation 
and DOX injections, a potential trend toward Cr supplementation providing protection 
with DOX administration in 1-EDL and 3-SOL were observed. The expression of cyt c of 
the 3-SOL was attenuated in 4% Cr-SAL and 4% Cr-DOX by 30.6% and 26.7%, 
respectively, compared to the 2% Cr-SAL and 2% Cr-DOX groups, respectively. Also, 
the attenuated casp-9 expression was observed in the 1-EDL, treated with the Cr loading 
diet treatment compared to the 2% Cr-DOX group. According to Hultman et al. (1996), 
the Cr loading treatment increases total Cr concentration in skeletal muscle compared to a 
steady amount of Cr supplemented. This finding may explain that the Cr loading 




compared to the 2% Cr treatment and thus may have attributed to prevent the initiation of 
apoptosis in this study. 
 The gradual increase in the casp-9 expression, although not significant (p>0.05), 
was observed in 1-SOL and 3-SOL with both the SAL and DOX injection. This finding 
can be explained by the dimerization of cleaved casp-9. When procaspase-9 becomes 
activated by Apaf-1, the cleaved casp-9 can lead to the activation of another procaspase-9 
that was next to for its dimerization. The overexpression of cleaved casp-9 led to a 48% 
increase in cleaved casp-9 expression in HeLa cells (Druskovic et al., 2006). 
Additionally, the SOL muscles have a higher percentage of type I muscle fibers, also 
known as slow-twitch fiber, compared to the EDL muscles (type IIb fiber/fast-twitch 
fiber) in Sprague-Dawley rats (Armstrong & Phelps, 1984). The type 1 muscle fibers, 
often utilized for aerobic activities, contain a higher oxidative capacity due to the higher 
concentration of mitochondria and capillaries while the type IIb fibers has a low 
mitochondrial density and less capillaries (Powers & Howley, 1995). Doxorubicin 
treatment often triggers ROS production from mitochondria via DNA damage and lipid 
peroxidation, which can lead to apoptosis (Min et al., 2015; Montaigne et al., 2011). 
Since SOL muscles have a higher mitochondrial density than the EDL muscles, DOX 
treatment could have been more effective with mitochondrial-ROS production and led to 
the trend toward higher expression cleaved casp-9 in the SOL muscles. 
 Previous studies have proposed the prevention of apoptosis with the Cr 
supplementation via increasing the activity of anti-apoptotic pathway (Caretti et al., 
2010), mitochondrial dysfunction signaling pathway (Ceddia & Sweeney, 2004) and 




defense mechanism of Cr, protein synthesis can be stimulated by Cr supplementation. In 
Ingwall, Weiner, Morales, Davis, and Stockdale study (1974), 5 mM of Cr supplement in 
cultured embryonic skeletal muscle with radioactive environment increased the synthesis 
rate of two major contractile protein, actin and myosin heavy chains but did not affect 
muscle degradation rate. Creatine supplement treatments did not significantly attenuate 
the initiator apoptotic enzyme expressions in either type I or type II skeletal muscles in 
the current study. With previous findings, Cr supplements may have affected protein 
synthesis more rather than preventing the apoptosis in oxidative environment.  
 Multiple studies report that the combination of Cr supplementation and exercise 
training increases body mass, anaerobic strength and power (M. Bemben et al., 2001), 
improves in speed (Skare et al., 2001), and increases in myofibrillar protein and MHC 
protein expressions (Willoughby & Rosene, 2001). Besides the improvement of exercise 
performance, Cr also possesses the antioxidant capacity for quenching ROS, specifically 
•O−2 and OONO
− according to previous research (Lawler et al., 2002). This antioxidant 
capacity of Cr was observed in oxidative skeletal muscles that was induced by acute 
exercise (Deminice & Jordao, 2012). However, Cr supplementation alone may not 
improve skeletal muscle function or increase in contractile muscle protein expression. 
According to Norman et al. (2006), a similar Cr supplement study without exercise was 
done in colorectal cancer patients for eight weeks, and the results showed that grip 
strength, knee extension strength, and hip flexion strength had no significant difference 
between the Cr intervention group, consisting of 20 g/day for one-week followed by 5 
g/day for 7 weeks, and the control group. The body cell mass (BCM) of the Cr 




results suggest that Cr supplementation alone cannot improve skeletal muscle functions 
and increase protein synthesis. In this study, exercise was also not performed along with 
the Cr supplement treatments. This may explain the increase in cyt c and casp-9 
expressions in the skeletal muscles because the Cr supplementation alone cannot induce 
its antioxidant effects without exercise. 
 Although the effects of Cr supplementation were not significant on the initiator 
apoptotic enzymes with the DOX treatment in the current study, many researchers have 
suggested Cr supplementation as a therapeutic agent in many disorders. According to 
Kley, Tarnopolsky, and Vorgerd (2013), Cr supplementation significantly increased in 
maximum voluntary contraction by 8.47% in patients suffering from muscle dystrophies. 
Also, the significantly higher number of patients answered “feeling better” with the Cr 
supplementation in the survey (p<0.05). Another study examined Cr’s effects in 
Parkinson’s disease, neurodegenerative disorder that affects motor systems in skeletal 
muscle. Patients with Cr supplementation combined with resistance training had 
significantly increased muscular strength in biceps curl, chest press, and leg extension 
(p<0.05). Additionally, muscle endurance for chest press and leg extension significantly 
increased by 38% and 95%, respectively, in the Cr supplementation group with resistance 
training (Hass, Collins, & Juncos, 2007). In Huntington disease involving mitochondrial 
dysfunction and oxidative injuries, Cr supplementation reduced the oxidative stress level 
in patients. Serum 8-hydroxy-2’-deoxyguanosine (8OH2’dG) was observed as a 
biomarker of DNA oxidative injury and its level significantly reduced by 9.11 ± 13.93 
pg/mL after 16 weeks of the Cr supplementation (5 g/day) (p<0.0042) (Hersch et al., 




should be investigated for future prevention and therapeutic mechanism for a variety of 
disorder even though the current study did not find significant effects of Cr 
supplementation in DOX treated skeletal muscles.  
 The limitation in this study was the uncertain and unequal amount of Cr 
consumed by rats. The DOX group especially could have had less amount of the Cr 
supplement compared to the SAL due to the loss of appetite, a common side effect of 
DOX (Coates et al., 1983). Another limitation of this study was the unequal sample sizes 
in each group due to the death of rats prior to tissue collections and removal of outliers 
from the data set. 
Further studies should investigate the effects of Cr supplementation and DOX 
administration on the initiation of apoptosis in skeletal muscles. The rate of protein 
synthesis and degradation should also be explored as previous studies discussed this 
along with the apoptotic enzyme expressions. In addition, DOX-induced ROS production 
should be measured to indicate the oxidative stress level in skeletal muscles. The 
consumption of the Cr supplement should be measured to standardize the amount of Cr 
stored in skeletal muscles as well. Exercise training should be also considered with Cr 
supplementation to enhance the effects of Cr. 
Conclusion 
 
The present study examined the effects of Cr supplementation and DOX 
administration on cyt c and casp-9 expressions in type I and type II skeletal muscles. In 
addition, the interaction between the Cr supplementation and DOX administration was 
examined in this study. There were no significant main effects of the Cr diet treatment or 




injection was also not significant. However, a potential trend toward Cr providing 
protection was observed in 1-EDL and 3-SOL by attenuating the increased expressions of 
cyt c and casp-9 with the Cr loading treatment. Future research should be conducted with 
the new interventions previously suggested to better understand the mechanisms of Cr 
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